Tvardi Therapeutics, Inc.
TVRD
$1.85
-$0.09-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.06M | -15.44M | -18.21M | -23.65M | -23.63M |
| Total Depreciation and Amortization | 95.00K | 95.00K | 95.00K | 95.00K | 95.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.37M | -11.06M | -5.89M | -4.15M | -4.39M |
| Change in Net Operating Assets | -427.00K | 4.73M | 508.00K | 5.06M | 2.88M |
| Cash from Operations | -25.03M | -21.67M | -23.50M | -22.65M | -25.05M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.47M | 5.78M | -10.08M | -15.08M | -20.43M |
| Cash from Investing | 20.47M | 5.78M | -10.08M | -15.08M | -20.43M |
| Total Debt Issued | -- | -- | -- | 28.30M | 28.30M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 108.00K | 529.00K | 532.00K | 531.00K | 424.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -429.00K | 23.78M | 22.17M | 20.88M | 21.30M |
| Cash from Financing | -321.00K | 24.31M | 22.70M | 49.71M | 50.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.88M | 8.41M | -10.88M | 11.98M | 4.54M |